241 related articles for article (PubMed ID: 21899592)
1. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab.
Burns AM; Green PJ; Pasternak S
J Cutan Pathol; 2012 Feb; 39(2):289-93. PubMed ID: 21899592
[TBL] [Abstract][Full Text] [Related]
2. Development of sarcoidosis during etanercept therapy.
Ishiguro T; Takayanagi N; Kurashima K; Matsushita A; Harasawa K; Yoneda K; Tsuchiya N; Miyahara Y; Yamaguchi S; Yano R; Tokunaga D; Saito H; Ubukata M; Yanagisawa T; Sugita Y; Kawabata Y
Intern Med; 2008; 47(11):1021-5. PubMed ID: 18520114
[TBL] [Abstract][Full Text] [Related]
3. [Pulmonary sarcoidosis developing during treatment with etanercept].
Kerjouan M; Jouneau S; Lena H; Luraine R; Desrues B; Delaval P
Rev Mal Respir; 2011 Mar; 28(3):360-4. PubMed ID: 21482342
[TBL] [Abstract][Full Text] [Related]
4. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab.
Dragnev D; Barr D; Kulshrestha M; Shanmugalingam S
BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24005973
[TBL] [Abstract][Full Text] [Related]
5. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.
Gifre L; Ruiz-Esquide V; Xaubet A; Gómez-Puerta JA; Hernández MV; Sanmartí R
Arch Bronconeumol; 2011 Apr; 47(4):208-12. PubMed ID: 20638761
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
[TBL] [Abstract][Full Text] [Related]
8. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication.
Tong D; Manolios N; Howe G; Spencer D
Intern Med J; 2012 Jan; 42(1):89-94. PubMed ID: 22389903
[TBL] [Abstract][Full Text] [Related]
9. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
[TBL] [Abstract][Full Text] [Related]
11. Etanercept-induced sarcoidosis in rheumatoid arthritis: FDG PET findings.
Nakajima R; Abe K; Nakajima A; Nishikawa T; Sakai S
Clin Nucl Med; 2015 Jan; 40(1):58-61. PubMed ID: 25188646
[TBL] [Abstract][Full Text] [Related]
12. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.
Daïen CI; Monnier A; Claudepierre P; Constantin A; Eschard JP; Houvenagel E; Samimi M; Pavy S; Pertuiset E; Toussirot E; Combe B; Morel J;
Rheumatology (Oxford); 2009 Aug; 48(8):883-6. PubMed ID: 19423648
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary sarcoidosis associated with etanercept therapy.
Farah RE; Shay MD
Pharmacotherapy; 2007 Oct; 27(10):1446-8. PubMed ID: 17896899
[TBL] [Abstract][Full Text] [Related]
14. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
[TBL] [Abstract][Full Text] [Related]
15. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
17. Development of sarcoidosis 6-month post discontinuation of etanercept: coincidence or real association?
Haroon M; Ryan JG; Harney S
Clin Rheumatol; 2011 Aug; 30(8):1095-8. PubMed ID: 21380931
[TBL] [Abstract][Full Text] [Related]
18. Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis.
Santoleri F; Sorice P; Lasala R; Rizzo RC; Costantini A
J Med Econ; 2014 May; 17(5):320-5. PubMed ID: 24641160
[TBL] [Abstract][Full Text] [Related]
19. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review.
Massara A; Cavazzini L; La Corte R; Trotta F
Semin Arthritis Rheum; 2010 Feb; 39(4):313-9. PubMed ID: 19147181
[TBL] [Abstract][Full Text] [Related]
20. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
Chastek B; Fox KM; Watson C; Gandra SR
Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
